

Audit 2023

Kontakt:

Tumorzentrum Hirslanden Zürich

Witellikerstrasse 40

8032 Zürich

T +41 44 387 96 62

tumorzentrum.hirslanden@hirslanden.ch

open studies

	<u>name of study</u>	<u>target group/ short description</u>
breast cancer	CanOn study	Patient registry for the use of cannabis in oncology.
	ELEANOR (Pierre Fabre)-study	A prospective, longitudinal, non-interventional study (NIS) that investigates real-world use of neratinib and its treatment management in patients with HR-positive, HER2-overexpressing/amplified breast cancer stage I-III having completed adjuvant trastuzumab-based therapy less than one year ago.
	EXPERT- study (ANZ 1601/ BIG 16-02)	Clinical trial which presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence (molecular luminal A-breast cancer)
	HER2CLIMB-05 (Seagen) study	A study of tucatinib or placebo with trastuzumab and pertuzumab for metastatic HER2+ breast cancer.
	IMPASSION 030-study (BIG 16-05)	A study comparing Atezolizumab (Anti PD-L1 Antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
	LidERA-study (Roche G042784)	a study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician's choice of adjuvant endocrine monotherapy in participants with estrogen receptor-positive, HER2-negative early breast cancer (LidERA Breast Cancer)
	OGIPRO-study	the study will engage anti-HER2 directed Trastuzumab biosimilar with a novel quality of ePRO and enable comparison of reliable reference real world patient data, thereby creating a basis for analytic research in order to promote the quality and efficiency of treatment
	POLAR-study (IBCSG 59/19)	Palbociclib for HR Positive / HER2-negative isolated locoregional recurrence of breast cancer (POLAR).
	SASCIA-study (Gilead)	Phase III, prospective, multi-center, randomized, open label, parallel group, study in patients with HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.
	SERENA 4-study (Astra Zeneca)	A comparative study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in patients with ER-Positive HER2 negative breast cancer who have not received any systemic treatment for advanced disease (SERENA-4).
TAXIS-study (SAKK 23/16)	Tailored AXillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS).	
VISION-study (SAKK 23/18)	Vacuum assisted biopsy Immediately before surgery as an Intra- or pre-Operative surrogate for patient response to neoadjuvant chemotherapy for breast cancer (VISION I)	

urogenital tumors

PCO study (Prostate Cancer Outcome)	Patient reported outcome measurement of patients with prostate cancer with global uniform patient questionnaire.
Ironman study	The IRONMAN registry collects information about a man's type of prostate cancer, their treatment and what side effects they may be experiencing.
Roche GLYCART study	Ex vivo modeling from fresh tumor samples.
SAKK 06/ 19 study	Intravesical recombinant BCG followed by perioperative chemo-immunotherapy for patients with MIBC

gastrointestinal tumors

EDIUM Studie	Patient-reported outcome study for colon cancer patients: Ergebnisqualität bei Darmkrebs: Identifikation von Unterschieden und Massnahmen zur flächendeckenden Qualitätsentwicklung (Quality of Experience in the case of colon cancer: identification of differences und actions to be taken for a comprehensive quality development)
ESODATA Studie	International standardized online database für outcomes of the patients receiving evaluation and/ or treatment für esophageal diseases of benign and malignant conditions.
Patient-derived organoid generation study	Patient-derived organoid generation in pancreatic cancer: a single centre, open-label, single arm feasibility study.
PREFER-Studie	Endoscopic management of patients with T1bN0M0 esophageal adenocarcinoma.
Qualitätssicherungstudie Duodenaltumore	quality assurance study of perioperative morbidity and post-surgical follow up of hepato-duodeno-pancreatic surgery.
Qualitätssicherungstudie Pankreaskarzinom	quality assurance study of perioperative morbidity and post-surgical follow up of pancreatic surgery.
ROBOT-2 study	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial
Roche GLYCART study	Ex vivo modeling from fresh tumor samples.
Tiger study	Distribution of lymph node metastases in esophageal carcinoma.

hematological systemic diseases

Abbvie Valor-Studie	A study to assess change in disease state in adult participants with acute myeloid leukemia (AML) ineligible for intensive chemotherapy in Switzerland and Austria receiving oral Venetoclax tablets (VALOR).
CAR-T Cell e-Pro Studie	Patient reported outcome study (application based) for CAR T-cell therapy patients.
EBMT-Register	Registry for patients that received a haematopoietic stem cell transplantation or CAR T-cell therapy.
PASS-study	A post-authorisation safety study that is carried out after a medicinal product has been authorised. The aim of the study is to obtain further information on a medicine's safety, or to measure the effectiveness of risk-management measures. A PAS study can be either a clinical trial or a non-interventional study.
SAKK EMCL-Registry	The registry of the European Mantle Cell Lymphoma study group - MCL: Disease pattern, treatment algorithms and mechanisms of relapse.

neuro-oncological tumors

Gliostar study	A study to evaluate safety and efficacy of L19TNF plus lomustine in patients with glioblastoma at first progression (GLIOSTAR).
----------------	---

gynaecological cancer

Meningiom-study	A population-based study on incidence, survival and molecular characteristics of meningioma in the Canton of Zurich, Switzerland.
PERGOLA-study	Pembrolizumab for newly diagnosed glioblastoma: a prospective, open-label, single-arm, multicenter phase II study.
ePro-study	Outcomes and Quality of Life using PROM and patient-centered data storage-an observational study.
MATAO study	Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III trial.
Roche GLYCART study	Ex vivo modeling from fresh tumor samples